Research article · 15 Jul 2025
Conference abstractPublished 2019
Memantine–cinnamic acid hybrids: Synthesis and in vitro evaluation of their effects against Alzheimer’s disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Despite of extensive investigations of finding causes for Alzheimer’s disease (AD), the etiology of this neurological disorder is rather complicated. Currently, the only drug approved for a treatment for moderate to severe Alzheimer’s disease is memantine (1-amino-3, 5-dimethyladamantane). This clinical drug is known as an open-channel, non-competitive N-methyl-D-aspartate (NMDA) receptor inhibitor. Considering the multifactorial nature of AD, the monotherapy concerning one-compound - one-target has not reached the desired effect. Therefore, in the recent years the hybrid-based approach has emerged as a promising therapy for Alzheimer’s disease. Following the multitarget approach, herein, amide-modified memantine with different substituted cinnamic acids were designed in order to investigate their effects in an in vitro AD model. Methodology and Theoretical Orientation: Synthesis: The target memantine amides (Fig. 1) were obtained in moderate yields (40–70%) based on the N-(3-dimethylaminopropyl)- N’-ethylcarbodiimide hydrochloride (EDC) as coupling agent and HOBt as catalyst (SHEEHAN, 1961). Neuroprotective effects of memantine derivatives: APPswe cells injured by copper, which triggers β-amyloid toxicity, were served as an AD model in vitro. The MTS assay was used to examine the protective effects of the memantine derivatives on copper injured APPswe cells. EC50 value was used to evaluate the efficacies for neuroprotection of the memantine hybrids as well as the positive drug memantine hydrochloride. Conclusion and Significance: The results demonstrated that the tested hybrid compounds showed protective effects on improving APPswe cell viability due to copperinduced toxicity. The EC50 ranging from (18.23 ± 1.08) μM to (35.24 ± 1.84) μM ACKNOWLEDGEMENTS: We gratefully acknowledge financial support from the BULGARIAN SCIENCE FUND (Project M 23/8).
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neurology and Neuroscience.
Research article · 15 Jul 2025
Diffuse Intrinsic Pontine Glioma: Unusually Long Survival of 28 Patients (From 3 Years to Over 29 Years) in Phase 2 Studies with Antineoplastons A10 and AS2-1
Short communication · 24 Jun 2025
The Role of High-Pressure Balloon Angioplasty in Treating Intracranial Atherosclerosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Aleksandra Tencheva”
- BylineArticles whose byline prints “Maya Chochkova”
- BylineArticles whose byline prints “Radoslava Kyoseva”
- BylineArticles whose byline prints “Hailun Jiang”
- BylineArticles whose byline prints “Rui Liu”
- BylineArticles whose byline prints “Yavor Mitrev”
- BylineArticles whose byline prints “Martin Sticha”
